Journal
EXPERIMENTAL AND MOLECULAR MEDICINE
Volume 50, Issue -, Pages -Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/s12276-018-0096-z
Keywords
-
Funding
- Bio & Medical Technology Development Program of the National Research Foundation (NRF) - Korean government (MSIP) [2014 M3A9D3034034]
- BK21-plus education program
Ask authors/readers for more resources
Antibody-drug conjugates (ADCs) can selectively deliver cytotoxic agents to tumor cells and are frequently more potent than naked antibodies. However, optimization of the conjugation process between antibodies and cytotoxic agents and characterization of ADCs are laborious and time-consuming processes. Here, we describe a novel ADC platform using a tetravalent bispecific antibody that simultaneously binds to the tumor-associated antigen and a hapten conjugated to a cytotoxic agent. We selected cotinine as the hapten because it is not present in biological systems and is inert and nontoxic. We prepared an anti-epidermal growth factor receptor (EGFR) x cotinine bispecific antibody and mixed it with an equimolar amount of cotinine-conjugated duocarmycin to form the ADC. This ADC showed significant in vitro and in vivo antitumor activity against EGFR-positive, cetuximab-refractory lung adenocarcinoma cells with KRAS mutations.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available